Abstract
The concept of a single chemical entity with desirable activity at more than one biological target is an attractive one. Increasingly, multiple complex biochemical pathways are implicated in a variety of diseases including cancer. Successful treatment of these conditions often depends on pharmaceutical intervention at multiple pathways, with a combination of different drugs. Designed multiple ligands (DMLs) are drugs which act at multiple biomolecular targets. Numerous terms have been used to describe such ligands, including multiple-target directed ligands, heterodimers, promiscuous drugs and pan-agonists. However, although there are many reported examples of multiple-targeting anti-cancer agents, no review of these has been presented to date. A huge variety of biological signalling-pathways, proteins and enzymes are currently targeted and implicated in the pathogenesis of cancer. This review will provide an overview of reported designed multiple ligands for cancer and an exploration of the advantages and drawbacks of such compounds. The review also provides brief commentaries on the biological processes and proteins that are currently targeted in cancer therapy and the potential for dual or triple targeting of these with designed multiple ligands.
Keywords: Cancer, Chemotherapy, Combination therapy, Conjugate, Designed multiple ligand, Dual-target, Enzyme inhibition, Multi-target, Multikinase inhibitors, Network pharmacology, Polypharmacy, Selectivity
Current Medicinal Chemistry
Title: Designed Multiple Ligands for Cancer Therapy
Volume: 18 Issue: 31
Author(s): N. M. O'Boyle and M. J. Meegan
Affiliation:
Keywords: Cancer, Chemotherapy, Combination therapy, Conjugate, Designed multiple ligand, Dual-target, Enzyme inhibition, Multi-target, Multikinase inhibitors, Network pharmacology, Polypharmacy, Selectivity
Abstract: The concept of a single chemical entity with desirable activity at more than one biological target is an attractive one. Increasingly, multiple complex biochemical pathways are implicated in a variety of diseases including cancer. Successful treatment of these conditions often depends on pharmaceutical intervention at multiple pathways, with a combination of different drugs. Designed multiple ligands (DMLs) are drugs which act at multiple biomolecular targets. Numerous terms have been used to describe such ligands, including multiple-target directed ligands, heterodimers, promiscuous drugs and pan-agonists. However, although there are many reported examples of multiple-targeting anti-cancer agents, no review of these has been presented to date. A huge variety of biological signalling-pathways, proteins and enzymes are currently targeted and implicated in the pathogenesis of cancer. This review will provide an overview of reported designed multiple ligands for cancer and an exploration of the advantages and drawbacks of such compounds. The review also provides brief commentaries on the biological processes and proteins that are currently targeted in cancer therapy and the potential for dual or triple targeting of these with designed multiple ligands.
Export Options
About this article
Cite this article as:
M. O'Boyle N. and J. Meegan M., Designed Multiple Ligands for Cancer Therapy, Current Medicinal Chemistry 2011; 18 (31) . https://dx.doi.org/10.2174/092986711797535344
DOI https://dx.doi.org/10.2174/092986711797535344 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Jumping on the Train of Personalized Medicine: A Primer for Non- Geneticist Clinicians: Part 3. Clinical Applications in the Personalized Medicine Area
Current Psychiatry Reviews Anticancer Antifolates: Current Status and Future Directions
Current Pharmaceutical Design One-Step Synthesis of 1H-1,2,3-Triazol-1-Ylmethyl-2,3-Dihydronaphtho[1,2-b]furan- 4,5-Diones
Current Organic Synthesis Association of Posture Instability with Dopamine Drop of Nigrostriatal System and Hypometabolism of Cerebral Cortex in Parkinson’s Disease
Current Neurovascular Research Reviewing the Role of Resveratrol as a Natural Modulator of Microglial Activities
Current Pharmaceutical Design CDC25A: A Rebel Within the CDC25 Phosphatases Family?
Anti-Cancer Agents in Medicinal Chemistry Nucleic Acids-based Nanotherapeutics Crossing the Blood Brain Barrier
Current Gene Therapy Future Prospects for Targeted Alpha Therapy
Current Radiopharmaceuticals Insulin-Like Growth Factor 2 - The Oncogene and its Accomplices
Current Pharmaceutical Design Subject Index to Volume 3
Current Gene Therapy Identification of Imidazoquinoline Derivatives as Potent Antiglioma Agents
Medicinal Chemistry Subject Index to Volume 4
Current Genomics Combination of Phytochemicals as Adjuvants for Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Nanoparticulate Formulations for Paclitaxel Delivery Across MDCK Cell Monolayer
Current Pharmaceutical Design Pharmacological Modulation of Sphingolipids and Role in Disease and Cancer Cell Biology
Mini-Reviews in Medicinal Chemistry Translational Optical Imaging in Diagnosis and Treatment of Cancer
Current Pharmaceutical Biotechnology Alternative Splice Variants of Survivin as Potential Targets in Cancer
Current Drug Discovery Technologies Resveratrol Protects β Amyloid-Induced Oxidative Damage and Memory Associated Proteins in H19-7 Hippocampal Neuronal Cells
Current Alzheimer Research MicroRNAs: Emerging Role in the Endogenous μ Opioid System
CNS & Neurological Disorders - Drug Targets Involvement of Targeting and Scaffolding Proteins in the Regulation of the EGFR/Ras/MAPK Pathway in Oncogenesis
Current Signal Transduction Therapy